FDA said on April 16 that it is revoking the emergency use authorization (EUA) for bamlanivimab—when administered alone—to be used for treatment of mild to moderate COVID-19 in adults and certain pediatric patients. 

Patients will be coming to pharmacists with questions and concerns as the recommendation to suspend use of the Janssen (Johnson & Johnson, J&J) vaccine remains in place.